Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

This study has been designed as a Phase I, open-label, dose finding study with a dose
escalation part and a dose expansion part in adult patients with selected advanced solid
tumors. The study treatment, TNO155, will be taken until the patient experiences unacceptable
toxicity, progressive disease and/or treatment is discontinued at the discretion of the
investigator or the patient or due to withdrawal of consent. Some patients will be
participating in a food effect investigation as an exploratory objective.

Inclusion Criteria:

1. Able to understand and voluntarily sign the ICF and able to comply with the study
visit schedule and the other protocol requirements.

2. Patient (male or female) ≥18 years of age willing to agree to not father a
child/become pregnant and comply with effective contraception criteria.

3. Must have progressed following standard therapy, or for whom, in the opinion of the
Investigator, no effective standard therapy exists, is tolerated or is appropriate.

4. ECOG (Eastern cooperative oncology group) performance status ≤2

Exclusion Criteria:

1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations.
(Exceptions are KRAS G12C CRC and KRAS G12C NSCLC)

2. History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO.

3. Any medical condition that would, in the investigator's judgment, prevent the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures.

4. Clinically significant cardiac disease.

5. Active diarrhea or inflammatory bowel disease

6. Insufficient bone marrow function

7. Insufficient hepatic and renal function.